Prospective appraisal of the prevalence of primary aldosteronism in hypertensive patients presenting with atrial flutter or fibrillation (PAPPHY Study): Rationale and study design

Journal of Human Hypertension

Volumn 27, Issue 3, 2013, Pages 158-163

  Rossi, G P ^a   Seccia, T M ^a   Gallina, V ^a   Muiesan, M L ^b   Leoni, L ^a   Pengo, M ^a   Ragazzo, F ^a   Caielli, P ^a   Belfiore, A ^c   Bernini, G ^d   Cipollone, F ^e   Cottone, S ^f   Ferri, C ^g   Giacchetti, G ^h   Grassi, G ⁱ   Letizia, C ^j   Maccario, M ^k   Olivieri, O ^l   Palumbo, G ^m   Rizzoni, D ^b   Rossi, E ⁿ   Sechi, L ^o   Volpe, M ^j   Mantero, F ^a   Morganti, A ^i,p   Pessina, A C ^a   more..

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

^c UNIVERSITY OF BARI   (Italy)

^d UNIVERSITY OF PISA   (Italy)

^e UNIVERSITY OF CHIETI   (Italy)

^f UNIVERSITY OF PALERMO   (Italy)

^g UNIVERSITY OF L'AQUILA   (Italy)

^h UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

ⁱ UNIVERSITY OF MILANO BICOCCA   (Italy)

^j SAPIENZA UNIVERSITY OF ROME   (Italy)

^k UNIVERSITY OF TURIN   (Italy)

^l UNIVERSITY OF VERONA   (Italy)

^m Legnano Hospital   (Italy)

ⁿ Divisione di Malattie Infettive   (Italy)

^o UNIVERSITY OF UDINE   (Italy)

^p UNIVERSITY OF MILAN   (Italy)

more..

Author keywords

Aldosteronism; Atrial fibrillation; High blood pressure; Plasma renin

Indexed keywords

ALDOSTERONE; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; HYDROCORTISONE; LOW MOLECULAR WEIGHT HEPARIN; MINERALOCORTICOID ANTAGONIST; POTASSIUM; PROCOLLAGEN; RENIN; SODIUM; STEROID; THYROTROPIN;

ADRENALECTOMY; ADULT; AGED; ALDOSTERONE BLOOD LEVEL; ALDOSTERONE RELEASE; ARTERIAL STIFFNESS; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CARDIOVERSION; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIASTOLIC BLOOD PRESSURE; DISEASE DURATION; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; FOLLOW UP; HEART ATRIUM FLUTTER; HEART MUSCLE FIBROSIS; HOLTER MONITORING; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERTENSION; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; PAROXYSMAL HEART ATRIUM FIBRILLATION; PLASMA RENIN ACTIVITY; POTASSIUM BLOOD LEVEL; POTASSIUM URINE LEVEL; PRACTICE GUIDELINE; PREDICTOR VARIABLE; PRIMARY HYPERALDOSTERONISM; PROSPECTIVE STUDY; QUALITY OF LIFE; RECURRENT DISEASE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SINUS RHYTHM; SODIUM BLOOD LEVEL; SODIUM URINE LEVEL; STEROID URINE LEVEL; STUDY DESIGN; SYSTOLIC BLOOD PRESSURE; THROMBOEMBOLISM; THYROTROPIN BLOOD LEVEL;

ALDOSTERONE; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; ATRIAL FLUTTER; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; ELECTRIC COUNTERSHOCK; EUROPE; HUMANS; HYPERALDOSTERONISM; HYPERTENSION; PREVALENCE; PROSPECTIVE STUDIES; QUALITY OF LIFE; RECURRENCE; RENIN; RESEARCH DESIGN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84874118496     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2012.21     Document Type: Article

References (36)

1. Rossi G P, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 2006;48: 2293-2300
2. Beevers D G, Brown J J, Ferriss J B, Fraser R, Lever A F, Robertson JI et al. Renal abnormalities and vascular complications in primary hyperaldosteronism. Evidence on tertiary hyperaldosteronism. Q J Med 1976;45: 401-410
3. Rossi G, Boscaro M, Ronconi V, Funder JW. Aldosterone as a cardiovascular risk factor. Trends Endocrinol Metab 2005;16: 104-107
4. Milliez P, Girerd X, Plouin P F, Blacher J, Safar M E, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005;45: 1243-1248
5. Porodko M, Auer J, Eber B. Conn's syndrome and atrial fibrillation. Lancet 2001;357: 1293-1294
6. Watson T, Karthikeyan V J, Lip G Y, Beevers DG. Atrial fibrillation in primary aldosteronism. J Renin Angiotensin Aldosterone Syst 2009;10: 190-194
7. Muiesan M L, Salvetti M, Monteduro C, Donato F, Rizzoni D, Agabiti-Rosei E. Various ways of calculating echocardiographic left ventricular mass and their relative prognostic values. J Hypertens 1998;16: 1201-1206
8. Vaziri S M, Larson M G, Lauer M S, Benjamin E J, Levy D. Influence of blood pressure on left atrial size. The Framingham Heart Study. Hypertension 1995;25: 1155-1160
9. Rossi G P, Sacchetto A, Pavan E, Palatini P, Graniero G R, Canali C et al. Remodeling of the left ventricle in primary aldosteronism due to Conn's adenoma. Circulation 1997;95: 1471-1478
10. Sun Y, Weber KT. Cardiac remodelling by fibrous tissue: Role of local factors and circulating hormones. Ann Med 1998;30(Suppl 1): 3-8
11. Ramires F J, Sun Y, Weber KT. Myocardial fibrosis associated with aldosterone or angiotensin II administration: Attenuation by calcium channel blockade. J Mol Cell Cardiol 1998;30: 475-483
12. Rossi G P, Di Bello V, Ganzaroli C, Sacchetto A, Cesari M, Bertini A et al. Excess aldosterone is associated with alterations of myocardial texture in primary aldosteronism. Hypertension 2002;40: 23-27
13. Franklin S S, Wachtell K, Papademetriou V, Olsen M H, Devereux R B, Fyhrquist F et al. Cardiovascular morbidity and mortality in hypertensive patients with lower versus higher risk: A LIFE substudy. Hypertension 2005;46: 492-499
14. Dahlof B, Devereux R B, Kjeldsen S E, Julius S, Beevers G, de Faire U et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002;359: 995-1003
15. Schmieder R E, Kjeldsen S E, Julius S, McInnes G T, Zanchetti A, Hua TA et al. Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: The VALUE trial. J Hypertens 2008;26: 403-411
16. Healey J S, Baranchuk A, Crystal E, Morillo C A, Garfinkle M, Yusuf S et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: A meta-Analysis. J Am Coll Cardiol 2005;45: 1832-1839
17. Schneider M P, Hua T A, Bohm M, Wachtell K, Kjeldsen S E, Schmieder RE. Prevention of atrial fibrillation by Renin-Angiotensin system inhibition a meta-Analysis. J Am Coll Cardiol 2010;55: 2299-2307
18. Rossi GP. Cardiac consequences of aldosterone excess in human hypertension. Am J Hypertens 2006;19: 10-12
19. Thrall G, Lane D, Carroll D, Lip GY. Quality of life in patients with atrial fibrillation: A systematic review. Am J Med. 2006; 119: 448.e1-448.e19
20. Sukor N, Kogovsek C, Gordon R D, Robson D, Stowasser M. Improved quality of life, blood pressure, and biochemical status following laparoscopic adrenalectomy for unilateral primary aldosteronism. J Clin Endocrinol Metab 2010;95: 1360-1364
21. European Heart Rhythm Association;European Association for Cardio-Thoracic Surgery, Camm A J, Kirchhof P, Lip G Y, Schotten U, Savelieva I, Ernst S et al. Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010;31: 2369-2429
22. Alhadramy O, Jeerakathil T J, Majumdar S R, Najjar E, Choy J, Saqqur M. Prevalence and predictors of paroxysmal atrial fibrillation on Holter monitor in patients with stroke or transient ischemic attack. Stroke 2010;41: 2596-2600
23. Huxley R R, Lopez F L, Folsom A R, Agarwal S K, Loehr L R, Soliman EZ et al. Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors: The Atherosclerosis Risk in Communities (ARIC) study. Circulation 2011;123: 1501-1508
24. Funder J W, Carey R M, Fardella C, Gomez-Sanchez C E, Mantero F, Stowasser M et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008;93: 3266-3281
25. Rossi GP. Medscape. A comprehensive review of the clinical aspects of primary aldosteronism. Nat Rev Endocrinol 2011;7: 485-495
26. Lang R M, Bierig M, Devereux R B, Flachskampf F A, Foster E, Pellikka PA et al. Recommendations for chamber quantification: A report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005;18: 1440-1463
27. Leung D Y, Chi C, Allman C, Boyd A, Ng A C, Kadappu KK et al. Prognostic implications of left atrial volume index in patients in sinus rhythm. Am J Cardiol 2010;105: 1635-1639
28. Oral H, Pappone C, Chugh A, Good E, Bogun F, Pelosi Jr. F et al. Circumferential pulmonary-vein ablation for chronic atrial fibrillation. N Engl J Med 2006;354: 934-941
29. Marchese P, Bursi F, Delle Donne G, Malavasi V, Casali E, Barbieri A et al. Indexed left atrial volume predicts the recurrence of non-valvular atrial fibrillation after successful cardioversion. Eur J Echocardiogr 2011;12: 214-221
30. Rossi G P, Pessina A C, Heagerty AM. Primary aldosteronism: An update on screening, diagnosis and treatment. J Hypertens 2008;26: 613-621
31. Rossi G P, Barisa M, Belfiore A, Desideri G, Ferri C, Letizia C et al. The aldosteronerenin ratio based on the plasma renin activity and the direct renin assay for diagnosing aldosterone-producing adenoma. J Hypertens 2010;28: 1892-1899
32. Campbell D J, Nussberger J, Stowasser M, Danser A H, Morganti A, Frandsen E et al. Activity assays and immunoassays for plasma Renin and prorenin: Information provided and precautions necessary for accurate measurement. Clin Chem 2009;55: 867-877
33. Rossi G P, Seccia T M, Palumbo G, Belfiore A, Bernini G, Caridi G et al. Withinpatient reproducibility of the aldosterone: Renin ratio in primary aldosteronism. Hypertension 2010;55: 83-89
34. Kageyama Y, Suzuki H, Saruta T. Effects of routine heparin therapy on plasma aldosterone concentration. Acta Endocrinol (Copenh) 1991;124: 267-270
35. Levey A S, Bosch J P, Lewis J B, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130: 461-470
36. Rossi G P, Belfiore A, Bernini G, Desideri G, Fabris B, Ferri C et al. Prospective evaluation of the saline infusion test for excluding primary aldosteronism due to aldosterone-producing adenoma. J Hypertens 2007;25: 1433-1442